ArTS Archivio della ricerca di Trieste

BERGAMO, ALBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.516
AS - Asia 4.787
EU - Europa 4.431
SA - Sud America 694
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 12
Totale 19.569
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.409
SG - Singapore 1.872
CN - Cina 1.137
PL - Polonia 774
UA - Ucraina 627
IT - Italia 588
SE - Svezia 583
BR - Brasile 531
HK - Hong Kong 499
VN - Vietnam 498
DE - Germania 379
KR - Corea 269
GB - Regno Unito 261
FI - Finlandia 255
FR - Francia 249
RU - Federazione Russa 240
TR - Turchia 156
BG - Bulgaria 144
IE - Irlanda 128
IN - India 79
AR - Argentina 71
NL - Olanda 57
BD - Bangladesh 48
CA - Canada 44
MX - Messico 41
CH - Svizzera 32
IQ - Iraq 30
JP - Giappone 26
ZA - Sudafrica 24
ES - Italia 23
MA - Marocco 23
EC - Ecuador 22
ID - Indonesia 21
CO - Colombia 19
PY - Paraguay 19
SA - Arabia Saudita 19
AT - Austria 17
BE - Belgio 15
UZ - Uzbekistan 15
PH - Filippine 14
EU - Europa 13
KE - Kenya 13
PK - Pakistan 12
VE - Venezuela 12
SN - Senegal 11
TW - Taiwan 11
RO - Romania 10
AU - Australia 9
JO - Giordania 9
TH - Thailandia 9
CL - Cile 8
DZ - Algeria 8
EG - Egitto 8
KZ - Kazakistan 8
MY - Malesia 8
GR - Grecia 6
HU - Ungheria 6
IL - Israele 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
NG - Nigeria 5
NP - Nepal 5
PT - Portogallo 5
QA - Qatar 5
UY - Uruguay 5
AL - Albania 4
IR - Iran 4
KW - Kuwait 4
PE - Perù 4
BW - Botswana 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
ET - Etiopia 3
HN - Honduras 3
JM - Giamaica 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LT - Lituania 2
MN - Mongolia 2
PA - Panama 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BJ - Benin 1
BM - Bermuda 1
CG - Congo 1
DJ - Gibuti 1
Totale 19.551
Salva come PNG Salva come JPEG
Città #
Singapore 1.164
Ann Arbor 857
Fairfield 793
Ashburn 778
Woodbridge 753
Houston 660
Warsaw 640
Jacksonville 566
Chandler 510
San Jose 502
Hong Kong 485
Wilmington 461
Seattle 333
Hefei 309
Beijing 271
Cambridge 268
Seoul 265
Princeton 247
Santa Clara 220
Boardman 197
Ho Chi Minh City 169
Chicago 158
Sofia 142
Trieste 133
Dublin 125
Los Angeles 125
Izmir 123
Zgierz 122
Columbus 118
Hanoi 118
Lauterbourg 110
Dearborn 94
Dallas 87
Milan 84
Buffalo 82
Moscow 82
The Dalles 75
San Diego 61
Helsinki 47
São Paulo 43
Frankfurt am Main 41
Munich 41
London 36
Council Bluffs 33
New York 33
Düsseldorf 29
Phoenix 29
Bern 26
Verona 26
Redwood City 25
Falls Church 22
Turku 22
Des Moines 21
Guangzhou 21
Nanjing 21
Orem 21
Tokyo 19
Atlanta 18
Da Nang 18
Norwalk 17
Miano 16
Rio de Janeiro 16
Chennai 15
Poplar 15
San Francisco 15
Shanghai 15
Brussels 14
Kunming 14
Mexico City 14
Denver 13
North Bergen 13
Tianjin 13
Biên Hòa 12
Casablanca 12
Haiphong 12
Montreal 12
Tashkent 12
Dakar 11
Hangzhou 11
Johannesburg 11
Nairobi 11
Redmond 11
Vienna 11
Zhengzhou 11
Amsterdam 10
Belo Horizonte 10
Costa Mesa 10
Curitiba 10
Dhaka 10
Dong Ket 10
Jinan 10
Andover 9
Auburn Hills 9
Brasília 9
Hải Dương 9
Nuremberg 9
Shenzhen 9
Toronto 9
Boston 8
Dagenham 8
Totale 13.355
Salva come PNG Salva come JPEG
Nome #
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 397
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 342
Chemical and Molecular Approach to Tumor Metastases 341
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 285
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 255
Long non-coding RNA gas5 and intestinal mmp2 and mmp9 expression: A translational study in pediatric patients with IBD 247
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 246
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 236
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 228
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 219
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 219
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma 218
Phototoxic Activity and DNA Interactions of Water-Soluble Porphyrins and Their Rhenium(I) Conjugates 217
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 212
New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity. 211
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 208
Complessi di Rutenio con elevata attività antitumorale 208
Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice 208
Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new Ru(II)-[9]aneS3 analogues. 202
Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen 201
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation 200
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 200
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 198
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 195
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 194
Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A 194
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A 192
Ruthenium complexes can target determinants of tumour malignancy 192
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 190
Towards Matched Pairs of Porphyrin-ReI/99mTcIConjugates that Combine Photodynamic Activity with Fluorescence and Radio Imaging 190
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir 189
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 185
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 185
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 185
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 183
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 183
New half sandwich Ru(II) coordination compounds for anticancer activity 183
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 181
Stimulation of GALT and Activation of Mesenteric Lymphonode Lymphocytes by a Modifìed Iysozyme in CBA Mice with Mca mammary carcinoma 180
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 180
Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice 180
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 178
Half-sandwich RuIIsingle bond[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity 178
Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. 176
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 175
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data 175
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 174
Cytofluorimetric analysis of gut-intraepitelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme 172
Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo 171
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 171
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 170
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 170
Ruthenium antimetastatic agents 169
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 168
Ruthenium complexes with high antitumoral and antimetastatic activities 167
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition 166
Metal-based antitumour drugs in the post-genomic era: what comes next? 166
Ruthenium dimeric compounds suitable as antimetastatic and antineoplastic agents 165
Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients 165
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and of cisplatin. 163
Photolabile RuIIHalf-Sandwich Complexes Suitable for Developing “Caged” Compounds: Chemical Investigation and Unexpected Dinuclear Species with Bridging Diamine Ligands 161
Ruthenium Anticancer Drugs 158
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. 157
Novel water-soluble 99mTc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging 156
Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds 155
Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer 155
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation 154
Synthesis, characterization and tumor cell growth inhibition of new transplatinum complexes with phosphane derivatives 153
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2 153
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferring. 150
DNA-adduct formation-guided design: thoughts about the future of metal based anticancer drugs 149
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 148
Linking the future of anticancer metal complexes to the therapy of tumour metastases 148
Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph nodelymphocytes of tumour bearing mice fed with egg-white lysozyme. 146
Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. 146
Ruthenium-based compounds and tumour growth control (Review) 145
Biological Properties of Irim, the iridium(III) analogue of (imidazolium(bisimidazole)tetrachlororuthenate) (ICR) 145
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity 144
In vitro cell cycle arrest,in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. 143
Tumor cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 141
Synthesis and Chemical-Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl [1,2,4]triazolo [1,5-a]pyrimidine) 141
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. 141
Antimetastatic properties and DNA interactions of novel class of dimeric Ru(III) compounds Na2[trans-RuCl4(Me2SO)2(μ-L)] (L=ditopic, non chelating aromatic N-ligand). A preliminary investigation 141
New anionic and neutral complexes of Ru(III) with nitrogen oxide 140
Chitosan-coated alginate micro-particles delivery of active principles through conventional pelleted food - A study in Tilapia (Oreochromis niloticus) 140
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. 139
Hyperphosphorylation Maintenance Drives the Time-Course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in KB Cells 139
Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas 135
PHARMACOLOGICAL APPROACHES TO SARS-CoV-2 INFECTION: FROM DRUG REPOSITIONING FOR COVID-19 TREATMENT TO DISEASE ARREST/PREVENTION WITH MoAbs AND NOVEL ANTIVIRALS 132
Lysozyme-induced transcriptional regulation of tnf-α pathway genes in cells of the monocyte lineage 127
Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im) and ruthenium uptake by tumour cells 126
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenantrolines and acyclovir or penciclovir 126
Modification of Lymphocytes of Peyer’s Patches-Mesentheric Lymphonodes Splean by Egg-White Lysozyme 125
Inhibition of endothelial cell functions and angiogenesis by the metastasis inhibitor NAMI-A 124
Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A 124
CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after shot treatment with NAMI-A in KB cells 121
Tumour cell uptake, G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells 119
The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy 116
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin 115
Identification and measurement of transferrin receptors in a T-cell lymphocyte population by a fluorescent ligand 112
Totale 17.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021421 0 0 0 0 0 0 0 0 0 184 52 185
2021/20221.276 49 103 64 128 22 96 71 56 172 137 103 275
2022/20231.589 181 179 124 202 155 297 3 152 199 10 64 23
2023/2024938 84 55 33 52 95 57 114 305 9 15 48 71
2024/20252.674 18 150 483 187 204 286 160 149 299 256 197 285
2025/20265.436 434 404 529 573 499 539 893 206 626 733 0 0
Totale 19.868